Related Experiment Videos
Hypertension and coronary artery disease: a therapeutic challenge
1University Department of Cardiovascular Studies, General Infirmary, Leeds, England.
Insights
Carvedilol effectively treats both essential hypertension and coronary artery disease (CAD) by managing blood pressure and reducing cardiac ischemia. This drug addresses common risk factors, offering a unified therapeutic approach for patients with coexisting conditions.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Essential hypertension and coronary artery disease (CAD) frequently coexist, presenting a significant therapeutic challenge.
- Hypertension is a primary risk factor for CAD development, while CAD presence worsens hypertension prognosis.
- Shared metabolic risk factors, including lipid abnormalities, carbohydrate intolerance, and obesity, accelerate both conditions.
Purpose of the Study:
- To evaluate carvedilol as a therapeutic agent for patients with coexisting hypertension and CAD.
- To assess carvedilol's efficacy in managing blood pressure and alleviating symptoms of myocardial ischemia.
Main Methods:
- Carvedilol, a third-generation beta-adrenoceptor antagonist, was administered to patients with hypertension and CAD.
- The study assessed carvedilol's effects on 24-hour blood pressure control, exercise-induced pressure increases, anginal pain, and electrocardiographic signs of ischemia.
Main Results:
- Carvedilol demonstrated 24-hour blood pressure control and suppressed exercise-induced pressure surges in hypertensive patients.
- The drug effectively relieved anginal pain and improved electrocardiographic markers of myocardial ischemia in CAD patients.
- Carvedilol reduced left ventricular workload, wall stress, and myocardial oxygen consumption, mitigating ischemia.
Conclusions:
- Carvedilol offers a dual therapeutic benefit for patients with coexisting hypertension and CAD.
- The drug effectively manages both conditions by controlling blood pressure and reducing cardiac ischemic events.
Abstract:
The coexistence of the syndromes of essential hypertension and coronary artery disease (CAD) poses a major but common therapeutic challenge. High blood pressure is one of the most potent risk factors for the early development of CAD. Conversely, the presence of CAD significantly worsens the predictive prognosis associated with high blood pressure. Moreover, metabolic risk factors for the acceleration of both syndromes are similar, particularly with regard to abnormalities of the blood lipid profile, carbohydrate intolerance, and obesity. It is clinically crucial, therefore, to direct drug therapy not only at the immediate alleviation of the symptoms and signs of each syndrome but also to control the cardiac and vascular risk factors common to both syndromes. Carvedilol is a third-generation vasodilating beta-adrenoceptor antagonist with advantageous ancillary pharmacologic properties for the treatment of the patient with high blood pressure complicated by CAD. The immediate advantages of the drug in the treatment of both syndromes are distinct. In the patient with high blood pressure, carvedilol controls the pressure throughout the 24 h of the day and suppresses the increase associated with exercise. In the patient with CAD, the drug is efficacious in relieving anginal pain and electrocardiographic signs of myocardial ischemia. By reducing blood pressure and heart rate and retarding their increases during exercise, the drug exhibits a potent ability to reduce left ventricular work, wall stress, myocardial oxygen consumption, and left ventricular myocardial ischemia. In the patient in whom both syndromes coexist, carvedilol affords a remedy for both.(ABSTRACT TRUNCATED AT 250 WORDS)